scholarly journals Rheumatoid Arthritis Induced by Botulinum Toxin Type A: A Case Report and Review of the Literature

2021 ◽  
Vol 8 (1) ◽  
Author(s):  
Yanyan G ◽  
◽  
Yupeng L ◽  
Yuanyuan L ◽  
Fangfang Z ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Botulinum Toxin ◽  
Side Effects ◽  
Clinical Application ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Interphalangeal Joint ◽  
Right Hand ◽  
The Right

Introduction: Botulinum Toxin Type A (BoNT/A) is a bacterial toxin commonly used in cosmetic therapy. Although there has been a great deal of clinical and basic research on the potential therapeutic applications of botulinum toxin there are few reports on its clinical toxicity and side effects. Patient Concerns: A previously healthy 26-year-old woman developed joint pain and redness in her right toe, swelling in the posterior left foot and the interphalangeal joint of the right index finger, occasional shoulder pain, and morning stiffness for 30 minutes daily, 6 months after BoNT/A injection. Diagnosis: Laboratory testing showed elevated Rheumatoid Factor (RF), anti-cyclic citrullinated peptide (anti-CCP), C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR). Doppler ultrasound examination of the right hand and both feet showed synovial hyperplasia of the right wrist, right second proximal interphalangeal joint, both ankles, and right first metatarsophalangeal joint, as well as bony erosion in a left intertarsal joint. Magnetic Resonance (MR) examination for right hand showed multiple joint changes of right hand and wrist, which included synovium thickening and enhancement. She was diagnosed as rheumatoid arthritis. Interventions: BoNT/A injection was stopped. Methotrexate 10mg was given once weekly and hydroxychloroquine 0.2g was given twice daily with subsequent remission of arthritis. Outcomes: At 12 months from diagnosis, patient reported complete joints remission. Conclusions: This is the first report of rheumatoid arthritis caused by botulinum toxin injection, and we speculate on the mechanism of its occurrence in this paper. In addition, we systematically introduce the latest research results on the development mechanism of BoNT/A causing RA. This review suggests that it is necessary to further explore the specific mechanism of RA or osteochondral injury caused by BoNT/A, which will not only help to improve the current understanding of the potential toxic and side effects of BoNT/A in clinical application, but also promote the standardization of clinical application of BoNT/A.

scholarly journals Botulinum toxin type A for the treatment of muscle contractures secondary to acute spinal cord injury in a young cat

2020 ◽  
Vol 6 (1) ◽  
pp. 205511692092264
Author(s):  
Robert I McGeachan ◽  
Tobias Schwarz ◽  
Danièlle A Gunn-Moore ◽  
Katia Marioni-Henry
Keyword(s):  
Spinal Cord ◽  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Clinical Signs ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Subacute Stroke ◽  
Thoracic Limb ◽  
Cord Injury ◽  
The Right

Case summary A 4-month-old male entire domestic shorthair cat presented for sudden onset of right thoracic monoparesis following a fall; within 18 h, the clinical signs progressed to non-ambulatory right hemiplegia with absent sensation in the distal right thoracic limb and left hemiparesis. MRI revealed changes consistent with a C6–C7 acute non-compressive nucleus pulposus extrusion with suspected secondary C5–C7 spinal cord haemorrhage. Rehabilitation exercises were started immediately after the diagnosis of acute spinal cord trauma. Sensation in the right thoracic limb improved and, with the help of a splint applied to that limb, the cat was ambulatory on all four limbs. Unfortunately, clinical signs started to progress over the course of 10 days. The cat developed progressive discomfort on manipulation of the right elbow and carpus, and a hyperflexion of the right carpus. Radiographs revealed no skeletal abnormalities. Muscle contractures were suspected. Under general anaesthesia the triceps and flexor muscles of the carpus and digits were injected with a total of 100 U of botulinum toxin type A (BTX-A). No complications were associated with the procedure and 24 h after the injection the carpal hyperflexion resolved. Relevance and novel information The use of BTX-A to treat muscle contractures in human medicine is an established and increasingly used technique. For example, in subacute stroke patients with a non-functional arm, BTX-A forearm injection appears to prevent disabling finger stiffness, likely by minimising the development of contractures. Here, we demonstrate that intramuscular BTX-A is an effective treatment for acquired muscle contractures in a cat.

Intravesical Electromotive Botulinum Toxin Type A Administration—Part II: Clinical Application

Urology ◽  
2011 ◽  
Vol 77 (2) ◽  
pp. 439-445 ◽  
Author(s):  
Abdol-Mohammad Kajbafzadeh ◽  
Hamed Ahmadi ◽  
Laleh Montaser-Kouhsari ◽  
Lida Sharifi-Rad ◽  
Farideh Nejat ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Clinical Application ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type

scholarly journals Treatment of Primary Axillary Hyperhidrosis with Botulinum Toxin Type A: Our Experience in 50 Patients from 2007 to 2010

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Stefano Scamoni ◽  
Luigi Valdatta ◽  
Claudia Frigo ◽  
Francesca Maggiulli ◽  
Mario Cherubino
Keyword(s):  
Botulinum Toxin ◽  
Side Effects ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Subjective Rating ◽  
Axillary Hyperhidrosis ◽  
Compensatory Hyperhidrosis ◽  
Iodine Test ◽  
Local Injections

Background. Local injections of Botulinum toxin type A (BTX-A) are an effective and safe solution for primary bilateral axillary hyperhidrosis. Traditional treatments are often ineffective and difficult to tolerate. This study was performed to assess the efficacy and safety of Botulinum toxin type A in the treatment of these diseases and to evaluate the reliability of patient’s subjective rating in the timing of repeat injections. Methods. From 2007 to 2008, we included in the study and treated a total of 50 patients, and we used the Minor’s iodine test and the hyperhidrosis diseases severity scale as initial inclusion criteria and also for evaluating the followup, comparing to patient’s subjective rating. We used also a specific questionnaire to evaluate the level of pain, the onset of the effect, any eventual adverse effect of the treatment, the onset of compensatory hyperhidrosis, and the global grade of satisfaction. The data were analyzed using standard statistical methods. Results. 88% of patients were totally satisfied and all patients repeated the treatment during all the study. The symptom-free interval was in median 6 months with an average improving of HDSS of 1.5 points. In 86%, there was a complete accordance between the subjective patient’s demand of the repetition of the treatment and the positivity to Minor test and HDSS. No major side effects happened. Conclusion. Local injections of Botulinum toxin type A (BTX-A) result in an effective and safe solution for bilateral axillary primary hyperhidrosis for the absence of significant morbidity, side effects, and lack of efficacy or duration. The only defects are the need of repetition of the treatment and relative costs.

scholarly journals Patient-Reported Side Effects of Intradetrusor Botulinum Toxin Type A for Idiopathic Overactive Bladder Syndrome

2011 ◽  
Vol 86 (1) ◽  
pp. 68-72 ◽  
Author(s):  
Ricarda M. Bauer ◽  
Christian Gratzke ◽  
Alexander Roosen ◽  
Yasmin Hocaoglu ◽  
Margit E. Mayer ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Side Effects ◽  
Overactive Bladder ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Overactive Bladder Syndrome ◽  
Patient Reported

scholarly journals Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated

2017 ◽  
Vol 75 (2) ◽  
pp. 87-91 ◽  
Author(s):  
Jean Pierre Mette Batisti ◽  
Alais Daiane Fadini Kleinfelder ◽  
Natália Bassalobre Galli ◽  
Adriana Moro ◽  
Renato Puppi Munhoz ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Side Effects ◽  
Hemifacial Spasm ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Term Effect ◽  
Long Term Effect

ABSTRACT Hemifacial spasm (HFS) is a common movement disorder characterized by involuntary tonic or clonic contractions of the muscles innervated by the facial nerve. Objective To evaluate the long-term effect of botulinum toxin type A (BTX-A) in the treatment of HFS. Methods A retrospective analysis of patients treated at the Movement Disorders Outpatient Clinic in the Neurology Service, Hospital de Clínicas, Federal University of Paraná, Curitiba, from 2009 to 2013 was carried out. A total of 550 BTX-A injections were administered to 100 HFS patients. Results Mean duration of improvement following each injection session was 3.1 months, mean latency to detection of improvement was 7.1 days and mean success rate was 94.7%. Patients were evaluated at an interval of 5.8 months after each application. Adverse effects, which were mostly minor, were observed in 37% of the patients at least once during follow-up. The most frequent was ptosis (35.1%). Conclusion Treatment of HFS with BTX-A was effective, sustainable and safe and had minimal, well-tolerated side effects.

Current and Emerging Treatments for Cervical Dystonia

CNS Spectrums ◽  
2000 ◽  
Vol 5 (S5) ◽  
pp. s1-s8 ◽  
Author(s):  
Stewart A. Factor ◽  
Mark F. Lew ◽  
Richard M. Trosch
Keyword(s):  
Botulinum Toxin ◽  
Side Effects ◽  
Cervical Dystonia ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Limited Range ◽  
Spasmodic Torticollis ◽  
Double Blind ◽  
Limited Range Of Motion

ABSTRACTCervical dystonia (CD), also known as spasmodic torticollis, is the most common of the focal dystonias. Muscle hypertrophy is present in nearly all patients, and neck pain is associated with CD in about 80% of patients. Remissions can occur in about 20% of patients, though most last under a year.Medical therapies have not generally worked well for patients with CD, and are typically associated with many side effects. Botulinum toxin (BT), which causes fewer side effects, has been considered the treatment of choice. Beyond medical therapy, various surgeries for CD have been performed for many decades. Of surgical treatments now in use, selective peripheral denervation is the most common.In CD, botulinum toxin type A (BT-A) targets pain, dystonic posturing, limited range of motion, and tremor. BT type B (BT-B) is a serotype of BT that is ontogenetically distinct from the type A toxin. There have been three randomized, multicenter, double-blind, placebo-controlled trials of BT-B. It appears that BT-B is a safe and effective treatment for patients with CD who are responsive or resistant to BT-A.

Sign in / Sign up

Export Citation Format

Share Document